Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

2MePI

Add links
From Wikipedia, the free encyclopedia

2MePI
Clinical data
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor weak partial agonist or functional antagonist
ATC code
  • None
Identifiers
  • 2-methyl-1,3,4,5-tetrahydropyrido[4,3-b]indole
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H14N2
Molar mass186.258 g·mol−1
3D model (JSmol)
  • CN1CCC2=C(C1)C3=CC=CC=C3N2
  • InChI=1S/C12H14N2/c1-14-7-6-12-10(8-14)9-4-2-3-5-11(9)13-12/h2-5,13H,6-8H2,1H3
  • Key:FYHWPFXPFFPQRT-UHFFFAOYSA-N

2MePI, also known as 2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole, is a serotonin receptor modulator of the pyridoindole (γ-carboline) family.[1] It is the pyridoindole homologue of the ibogalog (azepinoindole) ibogaminalog (DM-506).[1]

The drug acts as a weak partial agonist or functional competitive antagonist of the serotonin 5-HT2A receptor, with an affinity (Ki) of 95 nM, an EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) of 533 nM (32%), an apparent IC50Tooltip half-maximal inhibitory concentration of 3,100 to 18,000 nM, and a KB of 89 to 228 nM.[1] Compared to ibogaminalog, 2MePi had 5-fold lower affinity, 59-fold lower activational potency, and less than half the activational efficacy at the serotonin 5-HT2A receptor.[1] Results were analogous for 8MeO-2MePI against ibogainalog (8MeO-2MePI's ibogalog homologue).[1] These findings indicate that ibogalogs are the more optimal structural scaffold for serotonin 5-HT2A receptor agonism.[1]

2MePI was first described in the scientific literature by Matthias Liechti and colleagues in 2026.[1]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 Rudin D, Ren X, Liechti ME, Huang N, Arias HR (March 2026). "Ibogalogs Activate the 5-HT2A Receptor through a Mechanism Involving Outward and Inward Movements of the Respective Transmembrane Segment TM6 and TM7". Neurochemical Research. 51 (2) 115. doi:10.1007/s11064-026-04727-5. PMID 41870698.
Retrieved from "https://en.wikipedia.org/w/index.php?title=2MePI&oldid=1347844747"